Kornimate/medical-research-clean huggingface dataset:
the mobile health intervention in pulmonary arterial hypertension (move pah) study

Conditions: Pulmonary Arterial Hypertension

Summary: patients with pulmonary arterial hypertension (pah) have reduced health related quality of life (hrqol) and impaired exercise capacity. despite fourteen approved therapies, most patients die within ten years. increasing physical activity is highly efficacious in pah, resulting in six-minute walk distance (6mwd) and hrqol improvement that often exceeds the effect of medications. prior activity studies required inpatient rehabilitation, which is impractical, hard to sustain, and poorly scalable to a rare disease. the investigators propose a randomized trial of smart texts versus usual care for 6 months. the investigators will randomize 100 pah patients to the mhealth intervention or usual care. the investigators will test the effect of a text-based mhealth intervention on hrqol in pah using the pah-specific emphasis-10 questionnaire. the investigators will also test the effect of an mhealth intervention on exercise capacity, measured by a supervised home-based 6mwd test. finally, the investigators will examine the effect of the intervention on time to clinical worsening (composite of pah therapy escalation, pah hospitalization, and death) one year after randomization.


Eligibility criteria:
inclusion criteria: * adults aged 18 or older. * diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (pah), or pah due to simple congenital heart disease (i.e. atrial septal defect). * who functional class i-iii * stable pah-specific medication regimen for three months prior to enrollment. subjects with only a single diuretic adjustment in the prior three months will be included. adjustments in iv prostacyclin for side effect management are allowed. * forced vital capacity \>65% predicted with no or minimal interstitial lung disease based on reviews of imaging studies by pi and medical monitor. exclusion criteria: * prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity. * pregnancy * diagnosis of pah etiology other than idiopathic, heritable, or associated. * functional class iv heart failure * requirement of \> 2 diuretic adjustment in the prior three months. * preferred form of activity is not measured by an activity tracker (swimming, yoga, ice skating, stair master, or activities on wheels such as bicycling or rollerblading).
computer guided placement of zygomatic implants in two different approaches

Conditions: Atrophic Maxilla; Zygomatic Implants

Summary: evaluation of computer guided placement of zygomatic implants utilizing intra sinus versus extra sinus surgical approach for the reconstruction of atrophic maxilla. the expected benefit from the current study is to select the most suitable approach for zygomatic implant placement with the least postoperative complications

during the last ten years, there has been an increase in the number of edentulous patients looking for and seeking out rehabilitation. formerly, individuals with edentulous maxilla and mandibles were rehabilitated with removable complete dentures, but it was associated with poor patients' satisfaction. alveolar bone atrophy results from loss of bony support due to the physiological process that naturally takes place after tooth loss, especially in the upper arch. due to its shape and structure, the maxilla is an extremely challenging arch to reconstruct with dental implants. oral and maxillofacial surgeons began utilizing alternative methods to replace missing teeth with osseointegrated dental implants in atrophic maxilla. as a result, different methods were developed for handling of this issue, including tilted implants, sinus elevation, the use of pterygoid implants, the use of short implants and zygomatic implants.

Eligibility criteria:
inclusion criteria: 1. patients with severely atrophic edentulous upper arch (cawood class iv, v, vi) that could not be restored by other type of treatment 2. patients who had at least 8-12 mm vertical bone height in anterior maxilla to allow installation of 2 conventional implants. 3. lacking posterior maxillary bone support due to significant sinus pneumatistion 4. good systemic health (asa score i-ii) 5. highly motivated patients. exclusion criteria: 1. patient not willing to give his/her informed consent. 2. patients with systemic disease that did not permit the surgical procedure (including general anaesthesia). 3. patients with uncontrolled diabetes or under bisphosphonate therapy. 4. heavy smoker.(\> 20 cigarettes daily) 5. patient with psychiatric problems, severe bruxism or other parafunctional habits. 6. acute sinusitis. 7. malignancy or pathology in maxilla or zygoma.

Keywords: zygoamtic implants, dental implants, atrophic maxilla, intra sinus, extra sinus and full mouth rehabilitation
study in copd (chronic obstructive pulmonary disease) subjects to investigate safety, tolerability, and pharmacokinetics of ciprofloxacin after single dose inhalations of 50 mg and 75 mg ciprofloxacin inhalation powder

Conditions: Infection; Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in copd patients. in this study the 48.75 mg dose will be administered for the first time using a new high dose strength (i.e. one capsule containing 75 mg powder = 48.75 mg ciprofloxacin) formulation. safety investigations will focus on local tolerability in the lung and evaluate whether the patient can inhale the higher amount of powder compared to the lower dose strength. pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. results from this study will be used to decide whether the new dose strength is suitable for larger clinical trials planned for the copd patients population.


Eligibility criteria:
inclusion criteria: * adult subjects with copd, 40 - 75 years of age * all subjects must have a diagnosis of copd and must have airway obstruction with a post-bronchodilator forced expiratory volume in 1 sec (fev1) of \>/= 30% and \<= 80% of predicted and a post-bronchodilator fev1 / forced vital capacity (fvc) of \</= 70% * subjects must be current or ex-smokers with a smoking history of more than 10 pack-years * subjects must be able to perform technically acceptable pulmonary function tests during the study period as required in the protocol * subjects must be able to produce an sufficient amount of sputum during sputum induction at screening exclusion criteria: * subjects with a significant respiratory disease other than copd. * exacerbation within 8 weeks prior to screening * subjects with more than 1 copd exacerbation within 12 months prior to screening * subjects must have an fev1 of at least one liter * subjects with a history or physician's diagnosis of asthma. if a patient has a total blood eosinophil count \>/= 0.6 x 10\^9/l source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition. * subjects with hypersensitivity to the ciprofloxacin or to other quinolones and/or to inactive constituents of the inhalation powder * subjects with known hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution * subjects with a history of cystic fibrosis * subjects with clinically evident bronchiectasis * subjects taking any: * oral beta-adrenergic drugs or non cardioselective beta blockers, * oral glucocorticoids, * antihistamines or antileukotrienes prescribed for asthma, * oral cromolyn sodium or oral nedocromil sodium, * concomitant inhalative therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones

Keywords: 75 mg dose strength safety pharmacokinetics
effect of ketamine on postoperative clinical outcomes

Conditions: Colorectal Surgery

Summary: the purpose of this research is to evaluate the effectiveness of ketamine as an analgesic adjuvant in decreasing the narcotic (opioids) analgesics during surgery, on pain management and on the later recovery after surgery in patients undergoing colorectal surgery.

adjuvant is a drug that has few or no pharmacological effects by itself, but may increase the effectiveness or strength of other drugs when given at the same time.

Eligibility criteria:
inclusion criteria 1. patients scheduled to undergo small and/or large partial bowel resection via laparotomy or laparoscopy 2. willingness and ability to sign an informed consent document 3. no allergies to anesthetic or analgesic medications 4. 18 - 80 years of age 5. american society of anesthesiologists (asa) class i - iii adults of either sex exclusion criteria 1. inability to comprehend the pain assessment tools 2. patients with known allergy, hypersensitivity or contraindications to anesthetic or analgesic medications 3. patients with clinically-significant heart disease including arrhythmias and significant hypertension, brain aneurysms, prior history of cerebral vascular accident (cva), or chronic renal insufficiency 4. prior abdominal surgery 5. history of abdominal carcinomatosis 6. history of radiation enteritis; 7. patients with history of hepatic, renal, cardiac failure, organ transplant, or diabetes 8. patients with seizures 9. morbid obesity (body mass index \>40) 10. pregnant or lactating women 11. subjects with a history of alcohol or drug abuse within the past 3 months 12. any other conditions or use of any medication which may interfere with the conduct of the study 13. prophylactic nasogastric tube (ngt) use 14. individuals with significant manic disorders including: schizophrenia, or bipolar disorder or psychosis 15. individuals with asthma and/or thyroid diseases

Keywords: opioid fentanyl anesthetic adjuvant pain management perioperative outcomes constipation ileus colorectal
social cognition dysfunctions in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is usually responsible of cognitive and behavioral non-motor signs with a major impact on the quality of life. social cognition is a complex system relying on emotion recognition (neurons mirror system (nms)), the theory of mind (with its two parts: emotional and cognitive), but also on the social and cultural environment and the personal history. the first step in this model is represented by the nms, which seems to be altered in pd patients for both positive and negative emotions as shown in our preliminary study. the investigator purpose is to investigate the role of the treatment (levodopa and deep brain stimulation) on the functioning of the nms


Eligibility criteria:
inclusion criteria: for all participants: * man or woman * participant not objecting to participation in the study * age ≥ 30 and ≤ 70 years old specific inclusion criteria for patients: * patients with parkinson's disease with motor fluctuations and dyskinesias receiving deep-brain stimulation * patients able to understand the issues of the study exclusion criteria: for all participants: * person deprived of liberty by judicial or administrative decision * person subject to a legal protection measure (tutorship, curatorship) * person concurrently participating in another research project who may interfere with the results or conclusions of this study specific exclusion criteria for healthy volunteers * person presenting or having presented a neurological or psychiatric pathology * person with a serious medical condition * person who has exceeded the annual amount of compensation authorized for participation in research protocols

Keywords: parkinson disease emotional recognition deep brain stimulation
high-dose dexamethasone combining thalidomide versus dexamethasone mono-therapy for management of newly-diagnosed itp

Conditions: Immune Thrombocytopenia

Summary: the project was undertaking by qilu hospital of shandong university in china. in order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone for the treatment of adults with primary immune thrombocytopenia (itp), compared to conventional high-dose dexamethasone mono-therapy.

the investigators are undertaking a multicenter, randomized controlled trial of 200 primary itp adult patients from 5 medical centers in china. one part of the participants are randomly selected to receive thalidomide (given at a dose of 150mg for 15 consecutive days), combining with dexamethasone (given intravenously at a dose of 40 mg per day for 4 days, the others are selected to receive high-dose of dexamethasone treatment (given intravenously at a dose of 40 mg daily for 4 days). platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study. in order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone therapy compared to high-dose dexamethasone for the treatment of adults with itp.

Eligibility criteria:
inclusion criteria: * •newly diagnosed itp patients need of treatment(s) to minimize the risk of clinically significant bleeding primary itp confirmed by excluding other supervened causes of thrombocytopenia exclusion criteria: * •pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment hepatitis c virus, hiv, hbsag seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome

Keywords: thalidomide dexamethasone itp
yoga in the treatment of eating disorders: a randomized trial

Conditions: Anorexia Nervosa; Bulimia Nervosa

Summary: yoga facilitates the treatment of eating disorders by decreasing symptom severity over time.


Eligibility criteria:
inclusion criteria: * admitted to the anna westin house treatment facility of the emily program in mn during timeframe study is being run exclusion criteria: * declines participation in study
autologous sct followed by dendritic cell p53 vaccination in patients with limited stage small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: the purpose of this study is to determine whether p53 vaccination followed by high dose chemotherapy and autologous hct and t cell therapy significantly induces immune responses resulting in 1-year survival greater that the current 70%.


Eligibility criteria:
inclusion criteria: * histologically confirmed sclc who presented with limited stage (ls) at diagnosis. * measurable disease at the time of initial therapy * appropriate treatment for ls-sclc including radiotherapy and chemotherapy. * responsive disease to standard chemoradiation therapy as defined by recist * patients with cr after chemoradiation therapy are strongly recommended to be treated with prophylactic cranial irradiation * cbc with an absolute neutrophil count (anc) \>/= 1,000/ul, hemoglobin \>/= 8.0 g/dl and platelet count \>/= 75,000/ul. * normal prothrombin time (pt) and partial thromboplastin time (aptt), unless on monitored anticoagulation therapy for medical conditions not excluded in the trial. * liver enzymes: total bilirubin less than or equal to 2mg/dl; ast and alt less than 1.5x the upper limit of normal. * creatinine clearance of \>/= 60 ml/min * pulmonary: dlco greater than 50% * cardiac: left ventricular ejection fraction greater than 45% exclusion criteria: * patient with stable (sd) or progressive disease (pd) after 4 cycles of standard cisplatin and etoposide and concurrent chest irradiation * pregnant or lactating woman * hiv infection confirmed by nat * common variable immunodeficiency * active cns malignancy * active bacterial, fungal or viral infection * unfavorable psychosocial evaluation or history of poor compliance to prescribed medical care * prior history of autologous or allogeneic hematopoietic cell transplantation * presence of protocol specific comorbid conditions

Keywords: small cell lung cancer sclc limited stage small cell lung cancer
analysis of the acute mesenteric ischemia in a single institution over 10 years

Conditions: Acute Mesenteric Ischemia

Summary: acute mesenteric ischemia (ami) is a notorious disease with a high mortality, the diagnostic and management is truly multidisciplinary, but it is not the reality in many hospitals. the aim of this study is to analyse the results of the patients admitted with an ami in hospital de mar.

acute mesenteric ischemia (ami) is a notorious disease with a high mortality from 50 to 80%. even though ami is a relatively rare condition (1:1,000) the incidence rises exponentially with increasing age, in patients older than 75 years, the incidence of ami has been reported higher than that of acute appendicitis. ami patients benefit from early assessment in a surgical unit with capabilities to definitive management. the diagnosis and management of ami are truly multidisciplinary, requiring high index of suspicion and awareness from emergency department physicians, preferably computed tomography angiography with precise interpretation. the aim of this study is to analyse the results of the patients admitted with an ami in hospital de mar from january 2014 to december 2023.

Eligibility criteria:
inclusion criteria: * acute mesenteric ischemia exclusion criteria: * chronic mesenteric ischemia * ischemic colitis * bowel obstruction strangulation * inflamatory bowel necrosis

Keywords: mesenteric ischemia acute mesenteric ischemia abdominal pain elderly complications mortality
simultaneously targeting obesity and pain: the stop trial

Conditions: Obesity; Chronic Pain

Summary: the purpose of this study is to determine whether an integrated behavioral treatment approach can help overweight or obese individuals who also have chronic pain reduce their weight and manage their pain symptoms. the goal of this research is to develop better treatments for individuals with chronic pain and overweight or obesity. all participants in this study will receive treatment for weight management and/or pain symptoms. participants will be assigned at random (like we picked it blindly out of a hat) to receive either: (1) standard behavioral treatment for weight loss; or (2) standard behavioral treatment for pain management; or (3) integrated behavioral treatment for weight loss and pain.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 * body mass index (bmi) ≥ 25 * chronic, non-cancer pain (pain at a level ≥ 4 on a scale of 0-10 on a majority of the days for 6 months or more prior to study participation) exclusion criteria: * have an unstable medical or psychiatric condition * meet criteria for current substance abuse or dependence * meet the criteria for bulimia * non-fluent in spoken or written english * currently pregnant, pregnant within the past 6 months, trying to get pregnant in the next 3 months * demonstrate significant cognitive or sensorimotor impairment precluding treatment engagement * already participating in a similar structured diet or exercise program or pain self-management program or plans to begin such a program outside the study during the next month * at risk for significant adverse cardiovascular events with moderate activity * plans to relocate within the upcoming 12 months
a study to assess the efficacy and safety of ym060 in female patients with diarrhea-predominant irritable bowel syndrome (ibs)

Conditions: Diarrhea-predominant Irritable Bowel Syndrome

Summary: to demonstrate the superiority of ym060 to a placebo in global assessment of relief of overall ibs symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel syndrome (d-ibs).


Eligibility criteria:
inclusion criteria: 1. patients satisfying the rome iii diagnostic criteria 2. patients whose ≥25% of stools were loose or watery and \<25% of them were hard or lumpy stools 3. patients who have abdominal pain or discomfort 4. patients in whom after occurrence of ibs symptoms the following tests were conducted and in whom no organic changes were observed pancolonoscopy or contrast enema exclusion criteria: 1. patients with a history of surgical resection of the stomach, gallbladder, small intestine or large intestine 2. patients with a history or current evidence of inflammatory bowel disease 3. patients with a history or current evidence of colitis ischemic 4. patients with concurrent infectious enteritis 5. patients with concurrent hyperthyroidism or hypothyroidism 6. patients with concurrent active peptic ulcer 7. patients with other concurrent disease that may affect the digestive tract passage or large intestinal function or that is likely to interfere with proper assessment of ibs abdominal pain/discomfort

Keywords: ym060 ramosetron diarrhea-predominant irritable bowel syndrome
automated echocardiographic detection of coronary artery disease using artificial intelligence methods

Conditions: Coronary Artery Disease

Summary: the incidence rate and mortality of coronary artery disease are increasing year by year. exploring non-invasive, accurate, and widely applicable methods to screen and diagnosis is of great significance. new ultrasound techniques, such as non-invasive myocardial work, have been proven to be superior to traditional ultrasound techniques in screening and diagnosis. however, diagnostic analysis based on ultrasound video images is time-consuming and subjective. the progress of artificial intelligence technology in fully automated quantitative evaluation of video images provides the possibility for computer-aided design screening and diagnosis. at present, the application of artificial intelligence in computer-aided design is a cutting-edge issue in the field of cardiovascular disease research. the application of artificial intelligence technology in the construction of computer-aided diagnostic models based on ultrasound video images is still in its early stages.

1) clarify the value of new cardiac ultrasound techniques indicators in coronary artery disease diagnosis; 2) to achieve classification and detection of cardiac ultrasound sections; implementing automatic segmentation and recognition of the left ventricular cavity, left ventricular myocardium, and left atrial wall contours through the clas model; using the another model to achieve heart motion tracking and synthesizing velocity vector maps of the heart flow field. 3) verify and optimize the coronary artery disease fully automated artificial intelligence diagnostic model mentioned above.

Eligibility criteria:
inclusion criteria: patients with suspected coronary artery disease who plan to undergo coronary angiography exclusion criteria: patients with ①aortic valve stenosis, aortic valve replacement surgery, hypertrophic cardiomyopathy; ②severe heart valve disease, arrhythmia, cardiomyopathy, congenital heart disease; ③the quality of ultrasound images is poor.
temperature control during dialysis treatment

Conditions: Renal Failure, Chronic

Summary: the purpose is to measure the effect of glucose in the dialysis water on blood pressure, pulse rate, and plasma glucose with and without body temperature control

to clarify the influence of temperature in dialysis water on blood pressure and vasoactive hormones

Eligibility criteria:
inclusion criteria: 1. age \> 18 years, 2. both men and women, 3. chronic renal failure and dialysis treatment for at least three months exclusion criteria: 1. heart failure, 2. lung insufficiency, 3. chronic liver disease, 4. diabetes mellitus, 5. malignant disease, 6. nephrotic syndrome, 7. lack of compliance, 8. unwillingness til participate

Keywords: glucose in dialysis water, dialysis treatment, temperature
conecct (colorectal neoplasia endoscopic classification to chose the endoscopic treatment)

Conditions: Digestive System Disease

Summary: prospective study so as to evaluate conecct score to determine both histological tissue and therapeutic choice


Eligibility criteria:
inclusion criteria: * n/a exclusion criteria: * n/a